Frederick Locke, MD: CAR T-Cell Therapy in Relapsed/Refractory NHL
Based on results of the ZUMA-1 trial, axicabtagene ciloleucel was submitted to the FDA earlier this year for patients with chemotherapy-refractory, aggressive non-Hodgkin lymphomas....
Mathias Rummel, MD, PhD: Bendamustine-Rituximab “StiL” Beats R-CHOP for Indolent Lymphomas
Ten-year results from the randomized, phase III StiL trial show that bendamustine plus rituximab leads to longer progression-free survival than R-CHOP in patients with...
Saar Gill, MD: Combining CAR T-Cell Therapy With Ibrutinib in CLL Patients
Adding ibrutinib to treatment with CAR T-cell therapy was feasible, led to deeper remissions, and reduced the severity of cytokine release syndrome in patients...
Aaron Gerds, MD: Glasdegib and New Directions in Myelofibrosis Treatment
Dr. Gerds discusses results from an ongoing trial of glasdegib, a novel hedgehog inhibitor, in patients with heavily pretreated myelofibrosis and significant disease burden.
Nicholas J. Short, MD: Inotuzumab Plus Lower-Intensity Chemotherapy Safe, Effective in Older Patients with...
Dr. Short shares results from a “proof-of-concept” study of the combination of inotuzumab ozogamicin and mini-hyper-CVD chemotherapy in older patients with newly diagnosed acute...
Jeff P. Sharman, MD: Ublituximab Plus Ibrutinib Improves Response Rate in High-Risk CLL
The novel anti-CD20 monoclonal antibody ublituximab (when added to ibrutinib) yielded superior response rates than ibrutinib alone in patients with high-risk chronic lymphocytic leukemia....
Ruben Mesa, MD: Momelotinib Non-Inferior to Ruxolitinib in Myelofibrosis
Dr. Mesa reviews data from the SIMPLIFY 1 trial, which compared the novel JAK1/2 inhibitor momelotinib with ruxolintinib in patients with JAK inhibitor–naïve MF,...
Richard Stone, MD: New FLT3 Inhibitor Crenolanib Shows Promise in FLT3-Mutated AML
The FLT3 inhibitor crenolanib, when added to standard induction chemotherapy, was associated with high rates of minimal residual disease negativity in patients with FLT3-mutated...
Noopur Raje, MD: Denosumab Versus ZA for Myeloma-Related Bone Disease
Dr. Raje discusses results from a large phase III trial comparing denosumab with zoledronic acid for delaying the time to a skeletal-related complication in...
Ian Flinn, MD: Bendamustine Plus Rituxmab Outperforms R-CHOP In Long-Term BRIGHT Follow-up
For patients with non-Hodgkin lymphomas, bendamustine plus rituximab extended survival and duration of response, compared with R-CHOP or R-CVP, according to 5-year follow-up data...
Current Issue
July 2017, Volume 3, Issue 8
This issue features an interview with the FDA's Richard Pazdur, highlights from the 2017 ASCO Annual Meeting, a debate about minimal residual disease in myeloma, and more.
